Hemostemix Announces Important Manufacturing Process Refinements
November 08, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that is has completed refinements to its...
Hemostemix Announces OTCQB Listing and DTC Eligibility
October 30, 2018 09:07 ET
|
Hemostemix Inc.
CALGARY, Alberta, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce the Company has been approved for...
Hemostemix Announces Three Additional Sites Enrolled in Phase II Clinical Trial
October 09, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that it has received all approvals from three new...
Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders
September 27, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that at the Annual and Special Meeting of Shareholders...
Hemostemix Announces Addition to Its Clinical Trial Management Team
September 24, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that Catherine St. George has joined the Company as a...
Hemostemix Announces Two New Strategic Trial Sites in Texas
August 16, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM) is pleased to announce that it has received all approvals from two significant...
Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial
July 18, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, July 18, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has treated three additional patients including...
Hemostemix Formalizes World-Class Scientific Advisory Board
July 05, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, July 05, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX-V:HEM) is pleased to announce the formalization of its Scientific Advisory Board (“SAB”). ...
Hemostemix Announces Major Milestone Achieved With First 3 U.S. Trial Sites for Phase II Clinical Trial Open for Patient Enrollment
May 30, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, May 30, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has entered into agreements and has received all...
Hemostemix Announces New EU Patent Grant
May 23, 2018 08:30 ET
|
Hemostemix Inc.
CALGARY, Alberta, May 23, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE:HEM) is pleased to announce that it has been granted a new patent in the European...